Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARVNNASDAQ:CALTNASDAQ:GPCRNASDAQ:RAPP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARVNArvinas$8.43-1.4%$17.56$7.91▼$45.77$579.75M1.951.70 million shs2.20 million shsCALTCalliditas Therapeutics AB (publ)$40.00$40.00$15.25▼$43.00$1.19B1.7710,339 shsN/AGPCRStructure Therapeutics$21.05+3.2%$25.31$19.39▼$62.74$1.21B-2.35831,665 shs801,491 shsRAPPRapport Therapeutics$10.51+4.9%$13.54$6.43▼$29.74$384.41MN/A166,530 shs185,765 shsUnlock the Potential in Options TradingOptions trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARVNArvinas-5.32%-52.66%-51.64%-56.15%-81.60%CALTCalliditas Therapeutics AB (publ)0.00%0.00%0.00%0.00%+72.56%GPCRStructure Therapeutics-4.76%-13.30%-17.74%-34.72%-39.82%RAPPRapport Therapeutics+0.10%+24.01%-36.34%-46.62%+1,001,999,900.00%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARVNArvinas2.9292 of 5 stars4.31.00.00.02.12.50.6CALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/AN/AN/AN/AGPCRStructure Therapeutics1.9362 of 5 stars3.51.00.00.02.01.70.6RAPPRapport Therapeutics1.7957 of 5 stars3.50.00.00.02.51.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARVNArvinas 2.69Moderate Buy$37.47344.44% UpsideCALTCalliditas Therapeutics AB (publ) 2.00Hold$39.25-1.88% DownsideGPCRStructure Therapeutics 3.00Buy$81.29286.16% UpsideRAPPRapport Therapeutics 3.00Buy$35.00233.02% UpsideCurrent Analyst Ratings BreakdownLatest RAPP, ARVN, CALT, and GPCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/13/2025ARVNArvinasMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$48.00 ➝ $12.003/13/2025ARVNArvinasGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$57.00 ➝ $32.003/13/2025ARVNArvinasThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$70.00 ➝ $15.003/12/2025ARVNArvinasBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$82.00 ➝ $20.003/12/2025ARVNArvinasWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOverweight ➝ Overweight$60.00 ➝ $26.003/12/2025ARVNArvinasBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$54.00 ➝ $28.003/12/2025ARVNArvinasWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Neutral$57.00 ➝ $12.003/11/2025ARVNArvinasHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$81.00 ➝ $81.003/11/2025ARVNArvinasOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform3/7/2025ARVNArvinasCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$28.00 ➝ $19.002/28/2025GPCRStructure TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform(Data available from 3/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARVNArvinas$263.40M2.20N/AN/A$8.17 per share1.03CALTCalliditas Therapeutics AB (publ)$1.60B0.74N/AN/A$1.06 per share37.74GPCRStructure TherapeuticsN/AN/AN/AN/A$9.77 per shareN/ARAPPRapport TherapeuticsN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARVNArvinas-$198.90M-$2.77N/AN/AN/A-75.51%-33.75%-16.75%5/6/2025 (Estimated)CALTCalliditas Therapeutics AB (publ)-$43.96M-$1.85N/A8.68N/A-30.18%-212.04%-27.96%N/AGPCRStructure Therapeutics-$89.62M-$0.79N/AN/AN/AN/A-16.37%-15.68%5/8/2025 (Estimated)RAPPRapport Therapeutics-$34.79MN/A0.00N/AN/AN/AN/AN/A6/2/2025 (Estimated)Latest RAPP, ARVN, CALT, and GPCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/14/2025N/AGPCRStructure Therapeutics-$0.23N/AN/AN/AN/AN/A2/27/2025Q4 2024GPCRStructure Therapeutics-$0.23-$0.22+$0.01-$0.22N/AN/A2/11/2025Q4 2024ARVNArvinas-$1.07-$0.63+$0.44-$0.63$62.79 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARVNArvinasN/AN/AN/AN/AN/ACALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/AGPCRStructure TherapeuticsN/AN/AN/AN/AN/ARAPPRapport TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARVNArvinasN/A4.644.64CALTCalliditas Therapeutics AB (publ)9.442.692.59GPCRStructure TherapeuticsN/A27.6327.63RAPPRapport TherapeuticsN/A45.9145.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARVNArvinas95.19%CALTCalliditas Therapeutics AB (publ)2.83%GPCRStructure Therapeutics91.78%RAPPRapport TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipARVNArvinas5.23%CALTCalliditas Therapeutics AB (publ)2.20%GPCRStructure Therapeutics9.43%RAPPRapport TherapeuticsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARVNArvinas42068.77 million65.18 millionOptionableCALTCalliditas Therapeutics AB (publ)18029.79 million29.14 millionOptionableGPCRStructure Therapeutics13657.34 million51.86 millionOptionableRAPPRapport TherapeuticsN/A36.58 millionN/AN/ARAPP, ARVN, CALT, and GPCR HeadlinesRecent News About These CompaniesWendy B. Young Buys 6,000 Shares of Rapport Therapeutics (NASDAQ:RAPP) StockMarch 14 at 7:48 PM | marketbeat.comInsider Buying: Rapport Therapeutics (NASDAQ:RAPP) CFO Purchases 9,900 Shares of StockMarch 14 at 7:29 PM | marketbeat.comWendy B. Young Buys 6,000 Shares of Rapport Therapeutics (NASDAQ:RAPP) StockMarch 14 at 7:14 AM | insidertrades.comCorrection: Mise à disposition des éléments préparatoires à l'AG du 28/03/2025 - Rapport Financier Annuel 2024March 13 at 12:14 PM | globenewswire.comCorrection: Mise à disposition des éléments préparatoires à l'AG du 28/03/2025 - Rapport Financier Annuel 2024March 13 at 11:45 AM | globenewswire.comRapport Therapeutics, Inc.: Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 13 at 6:39 AM | finanznachrichten.deMise à disposition des éléments préparatoires à l'AG du 28/03/2025 - Rapport Financier Annuel 2024March 13 at 3:00 AM | globenewswire.comRapport Therapeutics sees cash runway through 2026March 12 at 5:34 AM | markets.businessinsider.comRapport Therapeutics Reports 2024 Financial Results and ProgressMarch 12 at 12:31 AM | tipranks.comRapport Therapeutics reports Q4 EPS (57c) vs. ($8.01) last yearMarch 11 at 9:40 PM | markets.businessinsider.comRapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides ...March 11 at 7:42 AM | gurufocus.comRapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 11 at 7:00 AM | globenewswire.comRapport Therapeutics appointment Jeffrey Sevigny as CMOMarch 7, 2025 | thepharmaletter.comRapport Therapeutics Inc trading resumesMarch 4, 2025 | markets.businessinsider.comRapport Therapeutics Inc trading halted, volatility trading pauseMarch 4, 2025 | markets.businessinsider.comRapport Therapeutics Appoints New CMO Amid Phase 2a UpdatesMarch 3, 2025 | tipranks.comRapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine DevelopmentMarch 3, 2025 | globenewswire.comRapport Therapeutics to Participate in Upcoming Investor ConferencesFebruary 24, 2025 | globenewswire.comRapport Therapeutics (RAPP) Expected to Announce Earnings on ThursdayFebruary 22, 2025 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Shares Down 8.5% - What's Next?February 19, 2025 | marketbeat.comRapport Therapeutics, Inc. (RAPP)February 15, 2025 | ca.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesPrice Targets on NVIDIA Rise in Front of EarningsBy Sarah Horvath | February 24, 2025View Price Targets on NVIDIA Rise in Front of EarningsWarren Buffett Swaps VOO for This Reliable Dividend StockBy Sarah Horvath | March 7, 2025View Warren Buffett Swaps VOO for This Reliable Dividend StockNVIDIA’s Hidden AI Play: The Truth Behind Its WeRide InvestmentBy Gabriel Osorio-Mazilli | February 14, 2025View NVIDIA’s Hidden AI Play: The Truth Behind Its WeRide InvestmentArcher Aviation Stock Skids: Mistaking Progress for Bad News?By Chris Markoch | February 24, 2025View Archer Aviation Stock Skids: Mistaking Progress for Bad News?Broaden Your ETF Exposure With These 3 Overlooked FundsBy Nathan Reiff | March 6, 2025View Broaden Your ETF Exposure With These 3 Overlooked FundsRAPP, ARVN, CALT, and GPCR Company DescriptionsArvinas NASDAQ:ARVN$8.43 -0.12 (-1.40%) Closing price 04:00 PM EasternExtended Trading$8.46 +0.03 (+0.31%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Calliditas Therapeutics AB (publ) NASDAQ:CALT$40.00 0.00 (0.00%) As of 03/13/2025Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.Structure Therapeutics NASDAQ:GPCR$21.05 +0.65 (+3.19%) Closing price 04:00 PM EasternExtended Trading$21.50 +0.45 (+2.14%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Rapport Therapeutics NASDAQ:RAPP$10.51 +0.49 (+4.89%) Closing price 04:00 PM EasternExtended Trading$11.03 +0.52 (+4.95%) As of 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead How Super Micro Computer Stock Is Defying the Market Sell-Off Palantir’s Deal With Archer Aviation Keeps AI’s Future in Focus D-Wave Quantum Stock Jumps on "Quantum Supremacy" News Is a Bottom Finally Forming in Rocket Lab Stock? Intel Stock Surges on New CEO – The Real Story Runs Deeper AMD Stock: Can the PC Refresh Cycle Spark a Rally? Ramaco Resources Pins Hopes on Coal's Untapped Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
